Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Merck_&_Co.
$1.85 billion |
| gptkbp:acquisitionYear |
2021
|
| gptkbp:focusesOn |
immunoregulatory therapeutics
|
| gptkbp:foundedIn |
2017
|
| gptkbp:founder |
gptkb:Anthony_Coyle
gptkb:Jo_Viney gptkb:John_Sundy Kerry Love |
| gptkbp:headquartersLocation |
gptkb:Watertown,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Pandion Therapeutics (2021)
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
PD-1 agonists
immune modulators |
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockSymbol |
gptkb:PAND
|
| gptkbp:bfsParent |
gptkb:Merck_&_Co.,_Inc.
|
| gptkbp:bfsLayer |
6
|